<DOC>
	<DOC>NCT00214604</DOC>
	<brief_summary>Evaluation of the efficacy of rosuvastatin 10mg, rosuvastatin 20mg and pravastatin 40mg in subjects with dysbetalipoproteinemia.</brief_summary>
	<brief_title>Type III Dysbetalipoproteinemia</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipoproteinemias</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type III</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Lipid Regulating Agents</mesh_term>
	<criteria>Diagnosis of dysbetalipoproteinemia defined as VLDLC/VLDLTG mass ratio &gt;0.35 at Visit 2 or the concurrence of mixed hyperlipidemia (fasting TC ≥ 200mg/dL, fasting TG ≥ 200mg/dL at Visits 2 and 3) and a genotype of ApoE published to be associated with dysbetalipoproteinemia Use of cholesterollowering drugs, lipid lowering dietary supplements or food additives after Visit 1 except in accordance with the protocol as coadministered therapy (i.e., a fenofibrate) with rosuvastatin 40mg at Weeks 30 to 36; current active liver disease or hepatic dysfunction, serum CK ≥ 3 times ULN (unless explained by exercise) anytime during dietary period, serum creatinine &gt; 2.0 mg/dL or a history of renal transplantation before the treatment phase, fasting triglyceride &gt; 1000 mg/dL at any time during the dietary leadin or a history of pancreatitis while on treatment for dysbetalipoproteinemia.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>